Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
31
2023 to 2026
Breakthrough
3
Accelerated
2
Priority review
21
Orphan
5
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 5 | 1 |
| 2024 | 7 | 2 |
| 2025 | 5 | 3 |
| 2026 | 7 | 1 |
31 approvals
Newest first. Hover a badge for what it means.
- Hibsago (Bepirovirsen Sodium) · GlaxosmithklineOct 20, 2026
To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy
- Hovilpri (Pritelivir Mesylate) · Aicuris Anti-InfectOct 9, 2026
To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies
- Utebzi (Tebipenem Pivoxil Hydrobromide) · GlaxosmithklineJun 17, 2026
To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options
- Zaynich (Cefepime Hydrochloride, Zidebactam) · Wockhardt Bio AGMay 29, 2026
To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms
- Xocova (Ensitrelvir) · ShionogiMay 29, 2026
To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19
- Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INCMay 22, 2026Original approval · BLA 761468NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis
- Idvynso (Doravirine, Islatravir) · MsdApr 20, 2026
To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine
- Favlyxa (Fluorouracil) · Avyxa HoldingsFeb 20, 2026Original approval · NDA 220201Approval letter
- Nuzolvence (Zoliflodacin) · Entasis TherapDec 12, 2025
To treat uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae
- Clotic (Clotrimazole) · Carwin Pharm AssocSep 26, 2025
- Inlexzo (Gemcitabine Hydrochloride) · Janssen BiotechSep 9, 2025
- Enflonsia (Clesrovimab-Cfor) · Merck Sharp DohmeJun 9, 2025
To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season
- Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDApr 30, 2025Original approval · BLA 761373Approval letter
- Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDApr 30, 2025Original approval · BLA 761425Approval letter
- Blujepa (Gepotidacin Mesylate) · GlaxosmithklineMar 25, 2025
To treat uncomplicated urinary tract infections
- Emblaveo (Avibactam Sodium, Aztreonam) · AbbvieFeb 7, 2025
- Daptomycin (Daptomycin) · Maia Pharms INCNov 21, 2024Original approval · NDA 217630Approval letter
- Orlynvah (Probenecid, Sulopenem Etzadroxil) · Iterum TherapOct 25, 2024
To treat uncomplicated urinary tract infections (uUTI)
- Prevymis (Letermovir) · MsdAug 30, 2024
- Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDJun 28, 2024Original approval · BLA 761373Approval letter
- Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDJun 28, 2024Original approval · BLA 761425Approval letter
- Xolremdi (Mavorixafor) · X4 PharmsApr 26, 2024
To treat WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)
- Zevtera (Ceftobiprole Medocaril Sodium) · IstxApr 3, 2024
To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia
- Rezdiffra (Resmetirom) · MadrigalMar 14, 2024Original approval · NDA 217785NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring
- Exblifep (Cefepime Hydrochloride, Enmetazobactam) · Orchid PharmaFeb 22, 2024
To treat complicated urinary tract infections
- Defencath (Heparin Sodium, Taurolidine) · CormedixNov 15, 2023
To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter
- Beyfortus (Nirsevimab-Alip) · Astrazeneca AbJul 17, 2023
To prevent respiratory syncytial virus (RSV) lower respiratory tract disease
- Paxlovid (Copackaged) (Nirmatrelvir, Ritonavir) · PfizerMay 25, 2023
To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19
- Xacduro (Copackaged) (Durlobactam Sodium, Sulbactam Sodium) · Entasis TherapMay 23, 2023
To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex
- Rezzayo (Rezafungin Acetate) · MundipharmaMar 22, 2023
To treat candidemia and invasive candidiasis
- Daptomycin (Daptomycin) · HikmaJan 30, 2023Original approval · NDA 217415Approval letter
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.